Novartis urges First Circuit not to revive sham litigation claim

A lower court correctly held that Novartis’s patent litigation against a generic drugmaker was not objectively baseless or motivated by anticompetitive intent, the pharmaceutical company told the US Court of Appeals for the First Circuit on Monday.

Get unlimited access to all Global Competition Review content